231 related articles for article (PubMed ID: 24612196)
1. Immunohistochemistry as a screening tool for ALK rearrangement in NSCLC: evaluation of five different ALK antibody clones and ALK FISH.
Hutarew G; Hauser-Kronberger C; Strasser F; Llenos IC; Dietze O
Histopathology; 2014 Sep; 65(3):398-407. PubMed ID: 24612196
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent.
Conklin CM; Craddock KJ; Have C; Laskin J; Couture C; Ionescu DN
J Thorac Oncol; 2013 Jan; 8(1):45-51. PubMed ID: 23196275
[TBL] [Abstract][Full Text] [Related]
3. Detection of ALK expression in non-small-cell lung cancer with ALK gene rearrangements--comparison of multiple immunohistochemical methods.
Zwaenepoel K; Van Dongen A; Lambin S; Weyn C; Pauwels P
Histopathology; 2014 Oct; 65(4):539-48. PubMed ID: 24621075
[TBL] [Abstract][Full Text] [Related]
4. Comparing four different ALK antibodies with manual immunohistochemistry (IHC) to screen for ALK-rearranged non-small cell lung cancer (NSCLC).
Shen Q; Wang X; Yu B; Shi S; Liu B; Wang Y; Xia Q; Rao Q; Zhou X
Lung Cancer; 2015 Dec; 90(3):492-8. PubMed ID: 26477969
[TBL] [Abstract][Full Text] [Related]
5. Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended.
Savic S; Diebold J; Zimmermann AK; Jochum W; Baschiera B; Grieshaber S; Tornillo L; Bisig B; Kerr K; Bubendorf L
Lung Cancer; 2015 Aug; 89(2):104-9. PubMed ID: 26056079
[TBL] [Abstract][Full Text] [Related]
6. Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer.
Rogers TM; Russell PA; Wright G; Wainer Z; Pang JM; Henricksen LA; Singh S; Stanislaw S; Grille J; Roberts E; Solomon B; Fox SB
J Thorac Oncol; 2015 Apr; 10(4):611-8. PubMed ID: 25789833
[TBL] [Abstract][Full Text] [Related]
7. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.
Alì G; Proietti A; Pelliccioni S; Niccoli C; Lupi C; Sensi E; Giannini R; Borrelli N; Menghi M; Chella A; Ribechini A; Cappuzzo F; Melfi F; Lucchi M; Mussi A; Fontanini G
Arch Pathol Lab Med; 2014 Nov; 138(11):1449-58. PubMed ID: 24885803
[TBL] [Abstract][Full Text] [Related]
8. Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression.
Kim H; Yoo SB; Choe JY; Paik JH; Xu X; Nitta H; Zhang W; Grogan TM; Lee CT; Jheon S; Chung JH
J Thorac Oncol; 2011 Aug; 6(8):1359-66. PubMed ID: 21587085
[TBL] [Abstract][Full Text] [Related]
9. Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): results of a multi-centre ALK-testing.
V Laffert M; Warth A; Penzel R; Schirmacher P; Jonigk D; Kreipe H; Schildhaus HU; Merkelbach-Bruse S; Büttner R; Reu S; Kerler R; Jung A; Kirchner T; Wölfel C; Petersen I; Rodriguez R; Jochum W; Bartsch H; Fisseler-Eckhoff A; Berg E; Lenze D; Dietel M; Hummel M
Lung Cancer; 2013 Aug; 81(2):200-6. PubMed ID: 23669200
[TBL] [Abstract][Full Text] [Related]
10. For staining of ALK protein, the novel D5F3 antibody demonstrates superior overall performance in terms of intensity and extent of staining in comparison to the currently used ALK1 antibody.
Taheri D; Zahavi DJ; Del Carmen Rodriguez M; Meliti A; Rezaee N; Yonescu R; Ricardo BF; Dolatkhah S; Ning Y; Bishop JA; Netto GJ; Sharma R
Virchows Arch; 2016 Sep; 469(3):345-50. PubMed ID: 27271275
[TBL] [Abstract][Full Text] [Related]
11. Cytology specimens offer an effective alternative to formalin-fixed tissue as demonstrated by novel automated detection for ALK break-apart FISH testing and immunohistochemistry in lung adenocarcinoma.
Rosenblum F; Hutchinson LM; Garver J; Woda B; Cosar E; Kurian EM
Cancer Cytopathol; 2014 Nov; 122(11):810-21. PubMed ID: 25099128
[TBL] [Abstract][Full Text] [Related]
12. Improving Selection Criteria for ALK Inhibitor Therapy in Non-Small Cell Lung Cancer: A Pooled-Data Analysis on Diagnostic Operating Characteristics of Immunohistochemistry.
Jiang L; Yang H; He P; Liang W; Zhang J; Li J; Liu Y; He J
Am J Surg Pathol; 2016 May; 40(5):697-703. PubMed ID: 26825369
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemistry with 3 different clones in anaplastic lymphoma kinase fluorescence in situ hybridization positive non-small-cell lung cancer with thymidylate synthase expression analysis: a multicentre, retrospective, Italian study.
Bironzo P; Melocchi L; Monica V; Trebeschi D; Barbieri F; Maiello E; Migliorino MR; Lombardi A; Tiseo M; Righi L; Graziano P; Rossi G; Novello S
Pathologica; 2022 Aug; 114(4):278-287. PubMed ID: 36083243
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemistry, fluorescence in situ hybridization, and reverse transcription-polymerase chain reaction for the detection of anaplastic lymphoma kinase gene rearrangements in patients with non-small cell lung cancer: potential advantages and methodologic pitfalls.
Demidova I; Barinov A; Savelov N; Gagarin I; Grinevitch V; Stroiakovaski D; Popov M; Laktionov K; Gutorov S; Smolin A; Olshanskaya Y; Obukhova T
Arch Pathol Lab Med; 2014 Jun; 138(6):794-802. PubMed ID: 24878018
[TBL] [Abstract][Full Text] [Related]
15. Reflex ALK immunohistochemistry is feasible and highly specific for ALK gene rearrangements in lung cancer.
Houang M; Toon CW; Clarkson A; Sioson L; Watson N; Farzin M; Selinger CI; Chou A; Morey AL; Cooper WA; O'Toole SA; Gill AJ
Pathology; 2014 Aug; 46(5):383-8. PubMed ID: 24842379
[TBL] [Abstract][Full Text] [Related]
16. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization.
Paik JH; Choe G; Kim H; Choe JY; Lee HJ; Lee CT; Lee JS; Jheon S; Chung JH
J Thorac Oncol; 2011 Mar; 6(3):466-72. PubMed ID: 21258247
[TBL] [Abstract][Full Text] [Related]
17. ALK status testing in non-small-cell lung carcinoma by FISH on ThinPrep slides with cytology material.
Minca EC; Lanigan CP; Reynolds JP; Wang Z; Ma PC; Cicenia J; Almeida FA; Pennell NA; Tubbs RR
J Thorac Oncol; 2014 Apr; 9(4):464-8. PubMed ID: 24736067
[TBL] [Abstract][Full Text] [Related]
18. Equivocal ALK fluorescence in-situ hybridization (FISH) cases may benefit from ancillary ALK FISH probe testing.
Selinger C; Cooper W; Lum T; McNeil C; Morey A; Waring P; Amanuel B; Millward M; Peverall J; Van Vliet C; Christie M; Tran Y; Diakos C; Pavlakis N; Gill AJ; O'Toole S
Histopathology; 2015 Nov; 67(5):654-63. PubMed ID: 25847523
[TBL] [Abstract][Full Text] [Related]
19. Antibody 1A4 with routine immunohistochemistry demonstrates high sensitivity for ALK rearrangement screening of Chinese lung adenocarcinoma patients: A single-center large-scale study.
Wang Q; Zhao L; Yang X; Wei S; Zeng Y; Mao C; Lin L; Fu P; Lyu L; Li Z; Xiao H
Lung Cancer; 2016 May; 95():39-43. PubMed ID: 27040850
[TBL] [Abstract][Full Text] [Related]
20. ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm.
Marchetti A; Di Lorito A; Pace MV; Iezzi M; Felicioni L; D'Antuono T; Filice G; Guetti L; Mucilli F; Buttitta F
J Thorac Oncol; 2016 Apr; 11(4):487-95. PubMed ID: 26916631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]